Sandoz has announced that it will no longer pursue a generic rival to GlaxoSmithKline’s Advair Diskus (fluticasone/salmeterol) asthma treatment for the US market.
Announcing that it had discontinued its development program for generic Advair, Sandoz referred to a US Food and Drug Administration...




